Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?

Can Arena's lorcaserin be a smoking cessation drug?

Mar 28, 2014 at 2:30PM

Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials followed by a supplemental New Drug Application filing, or simply through off-label use by physicians. For example, Questcor Pharmaceuticals' Acthar Gel could reach blockbuster status this year by growing prescriptions across a diversity of indications. GlaxoSmithKline's (NYSE:GSK) fish oil pill Lovaza, on the other hand, is believed to have achieved blockbuster status through off-label use in patients with only moderately high triglycerides. 

So, it's no surprise Arena Pharmaceuticals (NASDAQ:ARNA) and its marketing partner Eisai (NASDAQOTH:ESALY) are working diligently to expand the label of their anti-obesity medication Belviq (lorcaserin). Yesterday, Arena filed an 8-K announcing that lorcaserin is now being studied in a mid-stage trial as a potential anti-smoking drug, which will last approximately 12 weeks and enroll up to 600 patients. Because Arena's shares moved higher on this news, I think it's worthwhile to take a deeper look at the potential commercial impact of a label expansion for lorcaserin as an anti-smoking drug.

Smoking cessation as a commercial opportunity
The smoking cessation market, in the broad sense, is expected to grow to $1.2 billion by 2017 in the U.S. alone. However, this estimate includes smoking cessation aids such as nicotine patches, gums, and sprays. In terms of pharmaceuticals, the U.S. Food and Drug Administration, or FDA, has approved two drugs for smoking cessation, namely Pfizer's Chantix and GlaxoSmithKline's Zyban, aka Wellbutrin.

Chantix has seen sales top $700 million in the past, but the drug is now mired in controversy over potential suicides and cardiovascular risks. In fact, Pfizer had to dole out $273 million last year because of lawsuits stemming from suicides and other psychiatric problems.

Zyban's sales for smoking cessation are not easy to decipher because the drug is prescribed for a host of other indications. Moreover, the drug has also seen its fair share of controversy due to marketing practices, further clouding its true market potential as a pharmacotherapy for smoking cessation.

In sum, the market size for smoking cessation drugs is likely to be in the hundreds of millions, but it's difficult to put even a rough estimate on lorcaserin's market potential for this indication due to the aforementioned issues. Moreover, the biggest market opportunity according to Arena and Eisai lies in ex-U.S. markets, especially in Asia. Beyond estimating the number of smokers in ex-U.S. territories, however, we lack a decent comparable to estimate market size in a quantitative sense. In fact, Arena and Eisai have even refrained from placing a market value on this indication for lorcaserin. Even so, the fact that neither smoking cessation drug currently on the market appears to be effective over the long term shows there is a need for new pharmaceutical options. 

Could lorcaserin be the next anti-smoking drug?
Loracersin is a selective 5-HT2C agonist that targets a biochemical pathway known as the dopamine reward system. Simply put, lorcaserin is supposed to reduce cravings for food and drugs like nicotine. Preclinical studies on rats showed that lorcaserin significantly reduced the self-administration of nicotine, even in groups receiving relatively low doses of the drug. The current mid-stage study will evaluate if lorcaserin can effectively help patients refrain from smoking in the last four weeks of treatment, also known as the continuous quit rate. Given the large size and design of the trial, we should thus have a good feel for lorcaserin's effectiveness as a pharmacotherapy for smoking cessation before the year's end.

Foolish wrap-up
Because lorcaserin's primary indication as a treatment for chronic obesity has yet to pay off commercially, Arena and Eisai will need to explore alternative avenues to unlock the drug's value. An approval for smoking cessation would likely add hundreds of millions to the drug's annual sales, possibly outpacing its revenue stream for chronic obesity, if commercialization went well. And what's key to keep in mind is that the current host of smoking cessation drugs aren't particularly effective, and in the case of Chantix, serious side effects have curtailed the drug's use. As such, you should keep a close eye on lorcaserin's ongoing trial for smoking cessation as it unfolds in the coming months. If the clinical trials prove fruitful, my view is that this supplemental indication could be a major boost to the drug's commercial performance.  

Even if Arena has a great 2014 with add-on indications, it may have serious trouble keeping up with this top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Even if Arena has a great 2014 with add-on indications, it may have serious trouble keeping up with this top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers